Lund, Sweden, May 14, 2018: Follicum AB (“Follicum” or “the Company”) today announce that the company’s diabetes project is progressing as planned and the company has submitted an enhanced patent application for its novel peptide drug candidate class. A large amount of results have been processed to complete the application submitted in early May 2017. The results are unequivocally positive and show that the new peptide class has the potential to become a valuable addition to the current treatment of diabetes.
Follicum initially identified a new class of peptides that increase insulin secretion in several experimental models. A number of new peptides within this class have been developed to optimize the desirable properties. Several of these induce an improved insulin release which is also potentiated with increasing glucose concentration in in vitro trials. The potential of the peptides as drug candidates has also been confirmed in glucose tolerance tests where they have demonstrated a glucose lowering effect in animal models . In addition, the peptides have been shown to delay the onset of the disease in an animal model for Type I diabetes. These experimental studies have been conducted in collaboration with Follicum’s network at Lund University.
The next milestone in the diabetes project is to choose a drug candidate by the end of 2018/2019 and advance this candidate towards clinical trials.
Diabetes is rapidly increasing globally. The disease is characterized by poor blood sugar control due to defective insulin signaling, which causes serious sequelae such as cardiovascular disease, renal failure, obesity, blindness and diabetic foot ulcers. Diabetes as well as it’s accompanying illnesses represent a major burden, partly for the individual patient, but also for the entire health care system. There is thus an already large and growing global need for new therapies that address effective control of glucose levels in combination with preventive effects on the various diabetic complications. Follicum’s strategy is to drive a well-developed project in the diabetes field that is attractive to global partners.
For further information, please contact:
Jan Alenfall – CEO, Follicum AB
Telephone: +46 46 19 21 97
This information is information that Follicum is obliged to make public according to the EU Market Abuse Regulation. The information was provided through the agency of the contact persons above, for publication on the 14th of May, 2018.
About Follicum AB
Follicum is a biotech company focused on the discovery and development of peptide-based drugs. The primary focus is in hair growth stimulation, where Follicum has obtained very promising results with FOL-005 in a recently completed clinical trial. In diabetes, the drug candidate FOL-014 has demonstrated an increase in insulin release in pre-clinical models. The company was founded in 2011, and is based in Lund, Sweden. Follicum is listed on the Swedish small cap exchange Aktietorget since 2014. www.follicum.com